VivoSeq
Dermatology

Central Centrifugal Cicatricial Alopecia

3

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

Central Centrifugal Cicatricial Alopecia is an early-stage landscape with 3 programs across 2 companies. The most active players are Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Alnylam Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 2Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Deucravacitinib in the Treatment of Cicatricial Alopecias
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT07508488·20 enrolled
A Pilot Study to Assess Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT07487948·30 enrolled
A Pilot Study of Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
Active, not recruiting·WWake Forest University Health Sciences·Phase 1·NCT05416333·18 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)